Status:

COMPLETED

Clinical Performance of Stenfilcon A Versus Filcon II 3

Lead Sponsor:

CooperVision, Inc.

Conditions:

Myopia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Clinical Performance of Stenfilcon vs. Filcon II 3

Detailed Description

The objective of this study is to compare the comfort and clinical performance of Stenfilcon vs. Filcon II 3 compared to subject's habitual contact lenses. The null hypothesis is that there is no diff...

Eligibility Criteria

Inclusion

  • Subjects must satisfy the following conditions prior to inclusion in the study:
  • Based on his/her knowledge, must be in good general health. Be of legal age (18 years) or older.
  • Be able and willing to adhere to the instructions set forth in this protocol and complete all specified evaluation.
  • Read, indicate understanding of, and sign Written Informed Consent (Appendix 1)
  • Require a contact lens prescription between -0.50 and -6.00 and have no more than -.75dioptor (D) of astigmatism in both eyes
  • Achieve visual acuity of 6/9 or better in each eye with a spherical contact lens prescription.
  • An existing soft contact lens wearer of any modality.
  • Must be able to wear their lenses at least 6 full days over the 7 days; 14 hours per day, assuming there are no contraindications for doing so.
  • Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
  • No amblyopia.
  • No evidence of lid abnormality or infection (e.g. entropion, ectropion, chalazia, recurrent styes).
  • No clinically significant slit lamp findings (e.g. infiltrates or other slit lamp findings greater than Grade 2: corneal edema, tarsal abnormalities, and conjunctival injection).
  • No other active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, cornea \[infiltrates\], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology.)
  • No aphakia

Exclusion

  • Any of the following will render a subject ineligible for inclusion:
  • Neophytes, who have not worn lenses before
  • Greater than 0.75D of refractive astigmatism in either eye
  • Presence of clinically significant (grade 3 or above) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures.
  • Presence of ocular or systemic disease or need of medication which might interfere with contact lens wear.
  • Slit lamp findings that would contraindicate contact lens wear such as:
  • Pathological dry eye or associated findings
  • Pterygium, pinguecula or corneal scars within the visual axis
  • Neovascularization \> 0.75 mm in from the limbus
  • Giant papillary conjunctivitis (GPC) Grade 3 or above
  • Anterior uveitis or iritis (past or present)
  • Seborrheic eczema, seborrheic conjunctivitis
  • History of corneal ulcer or fungal infections
  • Poor personal hygiene
  • A known history of corneal hypoesthesia (reduced corneal sensitivity).
  • Contact lens best corrected Snellen visual acuities (VA) worse than 6/9
  • Aphakia, Keratoconus or a highly irregular cornea

Key Trial Info

Start Date :

January 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2013

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT01808209

Start Date

January 1 2013

End Date

May 1 2013

Last Update

August 3 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Aston

Birmingham, West Midlands, United Kingdom, B4 7ET